Trials of prostate-cancer screening are not worthwhile.

TY - JOUR

T1 - Trials of prostate-cancer screening are not worthwhile.

AU - Dubben, Hans-Hermann

PY - 2009

Y1 - 2009

N2 - About 3% of men in developed countries die from prostate cancer. No conclusive evidence, however, either supports or refutes the benefit of prostate-cancer screening. More than 200 000 participants are needed for a screening study with prostate-cancer-specific death as the endpoint. A relative reduction in prostate-cancer mortality of 25% leads to a decrease in absolute risk of less than 1%-a difference of 75 individuals between the control and screening group. Participant non-compliance and small inaccuracies in attributing cause of death need to be compensated for in study size, requiring several million participants. Screening trials with insufficient sample sizes might show a lowering of cancer-specific mortality but not detect increases in all-cause mortality related to screening. Studies of a manageable size have too little discriminatory power and last a long time. Furthermore, results become available decades after trial initiation, by which time they are probably antiquated. Whether screening for prostate cancer is beneficial cannot be assessed in trials, a statement that might also be true for other diseases with low specific mortality.

AB - About 3% of men in developed countries die from prostate cancer. No conclusive evidence, however, either supports or refutes the benefit of prostate-cancer screening. More than 200 000 participants are needed for a screening study with prostate-cancer-specific death as the endpoint. A relative reduction in prostate-cancer mortality of 25% leads to a decrease in absolute risk of less than 1%-a difference of 75 individuals between the control and screening group. Participant non-compliance and small inaccuracies in attributing cause of death need to be compensated for in study size, requiring several million participants. Screening trials with insufficient sample sizes might show a lowering of cancer-specific mortality but not detect increases in all-cause mortality related to screening. Studies of a manageable size have too little discriminatory power and last a long time. Furthermore, results become available decades after trial initiation, by which time they are probably antiquated. Whether screening for prostate cancer is beneficial cannot be assessed in trials, a statement that might also be true for other diseases with low specific mortality.

KW - Humans

KW - Male

KW - Prostatic Neoplasms diagnosis

KW - Cause of Death

KW - Clinical Trials as Topic

KW - Patient Compliance

KW - Sample Size

KW - Humans

KW - Male

KW - Prostatic Neoplasms diagnosis

KW - Cause of Death

KW - Clinical Trials as Topic

KW - Patient Compliance

KW - Sample Size

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 294

EP - 298

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 3

M1 - 3

ER -